TYRX Announces First U.S. Implantation of AIGISRx® R Fully Bioresorbable Antibacterial Envelope
8/7/2013 9:45:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc. announced today that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Vanderbilt Heart and Vascular Institute in Nashville, TN by Dr. Christopher R. Ellis. The AIGISRx R Antibacterial Envelope received U.S Food and Drug Administration (FDA) clearance on May 20, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by